Structural Modifications of the Antiinflammatory Oxicam Scaffold and Preparation of Anticancer Organometallic Compounds

Nonsteroidal antiinflammatory drugs (NSAIDs) have chemopreventive effects in several cancer types, and the oxicam-based NSAIDs meloxicam and piroxicam exhibit potential to treat cancer. We prepared a series of novel oxicams and coordinated them to RuII(cym)Cl and OsII(cym)Cl moieties (η6-p-cymene = cym). The oxicam ligands acted either as monodentate N-donors or bidentate N,O-chelators, depending upon the ligand structure as well as reaction conditions such as the pH value and solvent used in the reaction. The cytotoxic activity of the complexes toward carcinoma cells was investigated. The isoxazolyl motif-containing ligand 1 and its complexes with RuII(cym)Cl 1a and the Os analogue 1b proved to have anticancer activity with IC50 values in a range similar to that observed for the RuIII investigational drug IT-139, and in general the Os compounds were equally or even slightly more potent than the Ru derivatives. Since meloxicam is known as a selective inhibitor of COX-2, molecular docking studies were carr...

[1]  B. Rosner,et al.  Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses’ Health Studies , 2018, JAMA oncology.

[2]  Giuseppe Sciortino,et al.  Prediction of the interaction of metallic moieties with proteins: An update for protein‐ligand docking techniques , 2018, J. Comput. Chem..

[3]  Mahmoud Labib,et al.  Functionalization of Ruthenium(II)(η6 -p-cymene)(3-hydroxy-2-pyridone) Complexes with (Thio)Morpholine: Synthesis and Bioanalytical Studies. , 2017, ChemPlusChem.

[4]  M. Hanif,et al.  Anti-Inflammatory Oxicams as Multi-donor Ligand Systems: pH- and Solvent-Dependent Coordination Modes of Meloxicam and Piroxicam to Ru and Os. , 2017, Chemistry.

[5]  M. Hanif,et al.  Anticancer activity of Ru- and Os(arene) compounds of a maleimide-functionalized bioactive pyridinecarbothioamide ligand. , 2016, Journal of inorganic biochemistry.

[6]  Hannah U. Holtkamp,et al.  RuII(η6‐p‐cymene) Complexes of Bioactive 1,2‐Benzothiazines: Protein Binding vs. Antitumor Activity , 2016 .

[7]  R. Scopelliti,et al.  Nonsteroidal Anti-inflammatory-Organometallic Anticancer Compounds. , 2016, Inorganic chemistry.

[8]  B. Keppler,et al.  Half-sandwich ruthenium(II) biotin conjugates as biological vectors to cancer cells. , 2015, Chemistry.

[9]  L. Marnett,et al.  Oxicams, a class of nonsteroidal anti‐inflammatory drugs and beyond , 2014, IUBMB life.

[10]  M. Hanif,et al.  Anticancer Ruthenium(η 6 - p -cymene) Complexes of Nonsteroidal Anti-inflammatory Drug Derivatives , 2014 .

[11]  R. Spitale,et al.  Molecular targets of aspirin and cancer prevention , 2014, British Journal of Cancer.

[12]  S. Dhar,et al.  The prodrug platin-A: simultaneous release of cisplatin and aspirin. , 2014, Angewandte Chemie.

[13]  J. Keiser,et al.  DMSO-mediated ligand dissociation: renaissance for biological activity of N-heterocyclic-[Ru(η6-arene)Cl2] drug candidates. , 2013, Chemistry.

[14]  N. Cook,et al.  Alternate-Day, Low-Dose Aspirin and Cancer Risk: Long-Term Observational Follow-up of a Randomized Trial , 2013, Annals of Internal Medicine.

[15]  M. Hanif,et al.  Solution equilibrium studies on anticancer ruthenium(II)-η6- p-cymene complexes of 3-hydroxy-2(1H)-pyridones , 2013 .

[16]  J. Kaiser.  Will an aspirin a day keep cancer away? , 2012, Science.

[17]  M. Parvez,et al.  Microwave assisted synthesis and structure-activity relationship of 4-hydroxy-N'-[1-phenylethylidene]-2H/2-methyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides as anti-microbial agents. , 2011, European journal of medicinal chemistry.

[18]  Ingo Ott,et al.  Modulation of the biological properties of aspirin by formation of a bioorganometallic derivative. , 2009, Angewandte Chemie.

[19]  Thomas Stützle,et al.  Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS , 2009, J. Chem. Inf. Model..

[20]  Lawrence J Marnett,et al.  Structural and functional basis of cyclooxygenase inhibition. , 2007, Journal of medicinal chemistry.

[21]  Marcel L Verdonk,et al.  General and targeted statistical potentials for protein–ligand interactions , 2005, Proteins.

[22]  W. Isaacs,et al.  Cyclooxygenases in cancer: progress and perspective. , 2004, Cancer letters.

[23]  Haruki Nakamura,et al.  Announcing the worldwide Protein Data Bank , 2003, Nature Structural Biology.

[24]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[25]  R. Jaggi,et al.  Conjugation of desmethylnaproxen in the rat--a novel acyl glucuronide-sulfate diconjugate as a major biliary metabolite. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[26]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[27]  P. Luger,et al.  Structure and physicochemical properties of meloxicam, a new NSAID , 1996 .

[28]  J. Lombardino,et al.  Piroxicam and other anti‐inflammatory oxicams , 1982 .

[29]  I. Perillo,et al.  3‐Oxo‐1,2‐benzoisothiazoline‐2‐acetic acid 1,1‐dioxide derivatives. I. Reaction of esters with alkoxides , 1980 .

[30]  Norman L. Allinger,et al.  Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms , 1977 .

[31]  J. Lombardino,et al.  Potent anti-inflammatory N-heterocyclic 3-carboxamides of 4-hydroxy-2-methyl-2H-1,2-benzothiazine 1,1-dioxide. , 1973, Journal of medicinal chemistry.

[32]  J. Lombardino,et al.  Sudoxicam and related N-heterocyclic carboxamides of 4-hydroxy-2H-1,2-benzothiazine 1,1-dioxide. Potent nonsteroidal antiinflammatory agents. , 1972, Journal of medicinal chemistry.

[33]  J. Lombardino,et al.  Synthesis and antiinflammatory activity of some 3-carboxamides of 2-alkyl-4-hydroxy-2H-1,2-benzothiazine 1,1-dioxide. , 1971, Journal of medicinal chemistry.

[34]  P. Dyson,et al.  The development of RAPTA compounds for the treatment of tumors , 2016 .

[35]  Hannah U. Holtkamp,et al.  Organoruthenium and Osmium Anticancer Complexes Bearing a Maleimide Functional Group: Reactivity to Cysteine, Stability, and Cytotoxicity , 2015 .

[36]  P. Dyson,et al.  Arene ruthenium and pentamethylcyclopentadienyl rhodium and iridium complexes containing N,O-chelating ligands derived from piroxicam: Synthesis, molecular structure and cytotoxicity , 2014 .

[37]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[38]  Anthony K. Smith,et al.  Arene ruthenium(II) complexes formed by dehydrogenation of cyclohexadienes with ruthenium(III) trichloride , 1974 .